Joles, Jaap A.

Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 887

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 407

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 363

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 126

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 113

Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 102

Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial

Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

Tonneijck, L., Muskiet, M. H. A., Blijdorp, C. J., Smits, M. M., Twisk, J. W., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., Hoorn, E. J., et al. (2019) · American Journal of Physiology-Renal Physiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 57

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 47

Healthy Bone Marrow Cells Reduce Progression of Kidney Failure Better than CKD Bone Marrow Cells in Rats with Established Chronic Kidney Disease

Van Koppen, A., Joles, J. A., Bongartz, L. G., Van Den Brandt, J., Reichardt, H. M., Goldschmeding, R., Nguyen, T. Q., & Verhaar, M. C. (2012) · Cell Transplantation

Chronic Kidney Disease and DiabetesMesenchymal stem cell research

Cited by 39